Featured Stories

Do Pharmaceutical Acquisitions Undermine Innovation by Disrupting Human Capital?

Antitrust authorities increasingly assess mergers through the lens of innovation, particularly in research-intensive sectors such as pharmaceuticals. In new research, Carmine Ornaghi and Lorenzo Cassi show how mergers disrupt human capital and reduce innovation in what they call manslaughter acquisitions.

Recent Authors

Featured Stories

ProMarket's newsletter

Join our weekly email newsletter.

Announcements


February 19: How the Financial Sector is Rigged Against You and How to Fix It